Pharma Update

FY guidance confirmed - strong half year performance Base business with continued strong momentum; COVID sales washed-out by Q1 24 Roche Guidance¹ HY Results Pharma: Key products with strong growth and momentum from ongoing launches Diagnostics: Base business with solid growth Pharma: +8% in CER; +32% from products launched since 2015 Diagnostics: +6% in CER COVID-19 sales for Diagnostics and Pharma expected to decline by roughly CHF 5bn AHR² sales expected to erode by roughly CHF 1.6bn COVID-19 sales: CHF -2.7bn AHR² sales: CHF -0.6bn 1 At Constant Exchange Rates (CER); 2 AHR: Avastin, Herceptin, Rituxan/MabThera 18

View entire presentation